- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
Johnson & Johnson COVID-19 vaccine becomes the strongest vaccine?
Johnson & Johnson COVID-19 vaccine becomes the strongest vaccine? Just one shot, the results of Johnson & Johnson vaccine exceed expectations, or become the strongest COVID-19 vaccine?
Johnson & Johnson recently released the latest COVID-19 vaccine data. Professor Carlos del Rio of Emory University in the United States said, “If the Johnson & Johnson vaccine can really achieve single-dose immunization, then the vaccine will undoubtedly become the preferred vaccine worldwide.”
Subsequently, Johnson & Johnson said: It is possible to obtain emergency use authorization in the United States as early as next month, and 60 million doses of vaccine should be produced in April this year.
At the close of the day, Johnson & Johnson stock price was +1.21%.
Antibodies produced by Johnson & Johnson vaccine:
- First dose is twice as much as other vaccines,
- Second dose is three times as much
The results announced by Johnson & Johnson this time belong to a clinical Phase 1/2A trial, with data from 805 volunteers.
For volunteers aged 18-55 and 65 and older, Johnson & Johnson’s researchers randomly assigned high-dose, low-dose vaccines and placebos. Some of the 18-55 year old volunteers also received a second vaccination.
The test results show:
According to the latest research data in the New England Journal of Medicine, healthy adults aged 18 to 55 and 65 and older were vaccinated with high or low doses of the vaccine, while others were vaccinated with placebos. Johnson & Johnson’s single-dose new coronavirus vaccine is safe and has produced an effective immune response in young and elderly volunteers.
While publishing the data, Johnson & Johnson Chief Scientist Paul Stoffels said: “Compared with other leading COVID-19 vaccines (Pfizer, Moderna and AstraZeneca), one dose of Johnson & Johnson vaccine can produce more neutralizing antibodies, which is equivalent to two doses of other vaccines; if After receiving the second dose of Johnson & Johnson vaccine 2 months later, the number of neutralizing antibodies will triple.”
“The data from this experiment show that a single vaccination can produce persistent antibodies in the body, which is expected to be highly effective in defeating COVID-19.”
This data comes at a time when the Centers for Disease Control and Prevention (CDC) has expanded the scope of the COVID-19 vaccination population to include people 65 years and older and people with pre-existing diseases. The government is also changing the allocation of vaccine doses. the way.
If Johnson & Johnson’s vaccine is approved by the US Food and Drug Administration, it will be the third vaccine approved for use in the United States after Pfizer and Moderna.
It is expected to be approved in February, the first adenovirus vector COVID-19 vaccine:
It should be noted that there are currently two vaccines approved in the United States: Pfizer/BioNTech vaccine and Moderna vaccine.
Both of these are mRNA vaccines. The core is to use genetic instructions to teach cells to make specific proteins. One of the biggest advantages of mRNA technology is that it can be used to develop vaccines faster than traditional methods.
① Pfizer, BioNTech-mRNA vaccine
- Dosage: 2 doses, 28 days apart
- Price: US$19.50 per dose for the first 100 million doses
- Latest developments: the UK was approved and the US urgently approved the review on December 10
In terms of storage conditions, Pfizer-BioNTech vaccine is currently the fastest-growing COVID-19 vaccine and the most demanding one. It needs to be stored and transported at -94°F (-70°C), which requires a special freezer . At standard refrigeration temperatures, it can only be stored for up to 5 days.
Pfizer and BioNTech have signed a contract with the United States to provide 100 million doses of vaccine.
② Moderna——mRNA vaccine
- Dosage: 2 doses, 28 days apart
- Price: US$25-37 per dose
- Latest development: U.S. emergency approval review on December 17
In terms of storage conditions, Moderna vaccine can be stable for up to 30 days at 36-46 degrees Fahrenheit (2-8 degrees Celsius, which is approximately the temperature of a standard household or medical refrigerator), and can be at -4 degrees Fahrenheit (-20 degrees Celsius) Save for up to six months.
In contrast, the vaccine developed by Johnson & Johnson is the first adenovirus vector vaccine based on serotype 26 (Ad26).
③ Johnson & Johnson-adenovirus vector
- Dosage: 1 dose
- Price: USD 10 per dose
- Latest progress: Phase III clinical is in progress
In terms of storage conditions, this vaccine can be stored at minus 20°C for 2 years, and stored at 2-8°C under normal cold storage conditions for at least three months.
The Johnson & Johnson vaccine was originally high hopes, but due to delays in its research and development, after many vaccines have been used in the market, it is finally late!
As early as April, Johnson & Johnson announced that its subsidiary, Janssen Pharmaceuticals, has cooperated with the U.S. Biomedical Advanced Research and Development Administration to jointly invest more than $1 billion in COVID-19 vaccine research and development, and promised to provide 1 billion doses of vaccines worldwide.
Subsequently, the US pharmaceutical company EBS and Johnson & Johnson signed a five-year contract for the production of raw materials for the new coronavirus vaccine candidate.
Johnson & Johnson has also cooperated with the U.S. government and received a $1 billion investment. Johnson & Johnson Plan:
- Started the first in human clinical study in July;
- Get preliminary clinical data in December;
- The first batch of vaccines will be available in 2021Q1, which can meet emergency authorization.
However, things backfired. On October 12, according to a report by the US health media STAT News, Johnson & Johnson halted the Phase III vaccine trial due to unexplained symptoms of the vaccinators.
*The COVID-19 vaccine candidate whose clinical trial has been suspended this time is a recombinant adenovirus vector vaccine. The phase 3 clinical trial was launched on September 23. It is planned to recruit approximately 60,000 adult volunteers worldwide, in the United States and other regions of the world. Approximately 215 locations spread out.
Johnson & Johnson’s vaccine production schedule has been delayed by about two months from the original schedule, and it must wait until April to return to normal.
According to the original schedule, emergency use authorization may be obtained in the United States as early as next month, and 60 million doses of vaccine are expected to be produced in April this year.
At present, the global research and development of the COVID-19 vaccine is racing against time. The latest data from Johnson & Johnson’s vaccine undoubtedly injects a boost to the global fight against the epidemic.
In history, human beings have fought against the epidemic countless times. Although they have paid a certain price, they all ended in human victory.
The process of fighting the epidemic must be arduous, but the difficulties and changes experienced now are likely to become catalysts and accelerators for the development of the entire industry.
(source:internet, reference only)